Cargando…
Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures
OBJECTIVE: Among standard treatments for infantile spasms, adrenocorticotropic hormone (ACTH) is reported as the best treatment, but ACTH is ineffective in one‐half of the patients. To establish precision medicine, we examined pharmacoresistance of focal epileptic spasms (ES), generalized ES, and ge...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886099/ https://www.ncbi.nlm.nih.gov/pubmed/34773678 http://dx.doi.org/10.1002/epi4.12560 |
_version_ | 1784660576750796800 |
---|---|
author | Takahashi, Yukitoshi Ota, Akiko Tohyama, Jun Kirino, Tomoko Fujiwara, Yumi Ikeda, Chizuru Tanaka, Shigeki Takahashi, Jyunya Shinoki, Toshihiko Shiraga, Hiroshi Inoue, Takushi Fujita, Hiroshi Bonno, Motoki Nagao, Masayoshi Kaneko, Hideo |
author_facet | Takahashi, Yukitoshi Ota, Akiko Tohyama, Jun Kirino, Tomoko Fujiwara, Yumi Ikeda, Chizuru Tanaka, Shigeki Takahashi, Jyunya Shinoki, Toshihiko Shiraga, Hiroshi Inoue, Takushi Fujita, Hiroshi Bonno, Motoki Nagao, Masayoshi Kaneko, Hideo |
author_sort | Takahashi, Yukitoshi |
collection | PubMed |
description | OBJECTIVE: Among standard treatments for infantile spasms, adrenocorticotropic hormone (ACTH) is reported as the best treatment, but ACTH is ineffective in one‐half of the patients. To establish precision medicine, we examined pharmacoresistance of focal epileptic spasms (ES), generalized ES, and generalized ES combined with focal seizures, diagnosed based on the revised seizure classification of ILAE in 2017. METHODS: We conducted a retrospective nationwide study in Japan on the long‐term seizure outcome of ES. Long‐term seizure outcome was evaluated by seizure‐free rate, seizure‐free period, and Kaplan‐Meier curve. Seizure‐free was defined as seizure control for longer than 2 months. RESULTS: From the medical history of 501 patients, 325 patients had generalized ES only (GES group) at the start of the first treatment, 125 patients had generalized ES after focal seizure onset (FS‐GES group), seven patients had focal ES after focal seizure onset (FS‐FES group), and 24 patients had generalized ES combined with focal seizures after focal seizure onset (FS‐GES + FS group). Seizure‐free period of ES (generalized ES and focal ES) [mean (95% confidence interval)] was 2.7 (0.0‐5.4) months in GES group, 1.1 (0.1‐2.2) months in FS‐GES group, 1.0 (0.2‐1.9) months in FS‐GES + FS group, and 0.1 (−0.2‐0.5) months in FS‐FES group. Seizure‐free rate, seizure‐free period, and Kaplan‐Meier curve of generalized ES were almost the same in GES group and FS‐GES group, with characteristics of superior response to ACTH. Mean seizure‐free period of generalized ES combined with focal seizures was significantly shorter in FS‐GES + FS group than in GES group. Mean seizure‐free period of focal ES in FS‐FES group was extremely short with exceedingly early relapse. SIGNIFICANCE: Pharmacoresistance was different in generalized ES, focal ES, and generalized ES combined with focal seizures. ES with focal features or with focal seizures may have focal lesions, thus consider surgical options earlier in the course. |
format | Online Article Text |
id | pubmed-8886099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88860992022-03-04 Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures Takahashi, Yukitoshi Ota, Akiko Tohyama, Jun Kirino, Tomoko Fujiwara, Yumi Ikeda, Chizuru Tanaka, Shigeki Takahashi, Jyunya Shinoki, Toshihiko Shiraga, Hiroshi Inoue, Takushi Fujita, Hiroshi Bonno, Motoki Nagao, Masayoshi Kaneko, Hideo Epilepsia Open Original Articles OBJECTIVE: Among standard treatments for infantile spasms, adrenocorticotropic hormone (ACTH) is reported as the best treatment, but ACTH is ineffective in one‐half of the patients. To establish precision medicine, we examined pharmacoresistance of focal epileptic spasms (ES), generalized ES, and generalized ES combined with focal seizures, diagnosed based on the revised seizure classification of ILAE in 2017. METHODS: We conducted a retrospective nationwide study in Japan on the long‐term seizure outcome of ES. Long‐term seizure outcome was evaluated by seizure‐free rate, seizure‐free period, and Kaplan‐Meier curve. Seizure‐free was defined as seizure control for longer than 2 months. RESULTS: From the medical history of 501 patients, 325 patients had generalized ES only (GES group) at the start of the first treatment, 125 patients had generalized ES after focal seizure onset (FS‐GES group), seven patients had focal ES after focal seizure onset (FS‐FES group), and 24 patients had generalized ES combined with focal seizures after focal seizure onset (FS‐GES + FS group). Seizure‐free period of ES (generalized ES and focal ES) [mean (95% confidence interval)] was 2.7 (0.0‐5.4) months in GES group, 1.1 (0.1‐2.2) months in FS‐GES group, 1.0 (0.2‐1.9) months in FS‐GES + FS group, and 0.1 (−0.2‐0.5) months in FS‐FES group. Seizure‐free rate, seizure‐free period, and Kaplan‐Meier curve of generalized ES were almost the same in GES group and FS‐GES group, with characteristics of superior response to ACTH. Mean seizure‐free period of generalized ES combined with focal seizures was significantly shorter in FS‐GES + FS group than in GES group. Mean seizure‐free period of focal ES in FS‐FES group was extremely short with exceedingly early relapse. SIGNIFICANCE: Pharmacoresistance was different in generalized ES, focal ES, and generalized ES combined with focal seizures. ES with focal features or with focal seizures may have focal lesions, thus consider surgical options earlier in the course. John Wiley and Sons Inc. 2021-11-19 /pmc/articles/PMC8886099/ /pubmed/34773678 http://dx.doi.org/10.1002/epi4.12560 Text en © 2021 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Takahashi, Yukitoshi Ota, Akiko Tohyama, Jun Kirino, Tomoko Fujiwara, Yumi Ikeda, Chizuru Tanaka, Shigeki Takahashi, Jyunya Shinoki, Toshihiko Shiraga, Hiroshi Inoue, Takushi Fujita, Hiroshi Bonno, Motoki Nagao, Masayoshi Kaneko, Hideo Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures |
title | Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures |
title_full | Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures |
title_fullStr | Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures |
title_full_unstemmed | Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures |
title_short | Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures |
title_sort | different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886099/ https://www.ncbi.nlm.nih.gov/pubmed/34773678 http://dx.doi.org/10.1002/epi4.12560 |
work_keys_str_mv | AT takahashiyukitoshi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT otaakiko differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT tohyamajun differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT kirinotomoko differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT fujiwarayumi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT ikedachizuru differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT tanakashigeki differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT takahashijyunya differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT shinokitoshihiko differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT shiragahiroshi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT inouetakushi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT fujitahiroshi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT bonnomotoki differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT nagaomasayoshi differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures AT kanekohideo differentpharmacoresistanceoffocalepilepticspasmsgeneralizedepilepticspasmsandgeneralizedepilepticspasmscombinedwithfocalseizures |